 |
 Jim Weiss |
Healthcare marketing and communications network W2O Group today announced that it has rebranded under a new name, Real Chemistry.
The independent agency, in a statement, said the name change addresses the disruption facing the healthcare sector since the outbreak of the COVID-19 pandemic, an environment in which information and services are increasingly delivered via intelligent technologies and one where the patient wields more control than ever.
“Innovation in healthcare has never moved faster or been more important,” Real Chemistry founder and CEO Jim Weiss told O’Dwyer’s. “That is why this moment is about so much more than a new name or approach. It’s about how our ethos of action, our two decades of intentional evolution and our drive for constant improvement helped us create what we see as the real chemistry between people and the brands born to change their lives.”
The San Francisco-headquartered network, which was founded in 2001, is the number-one independent healthcare PR firm, according to O’Dwyer’s annual rankings, accounting for about $219 million in net fees in 2019.
A breakthrough is not successful merely because it works. It succeeds when people and health systems can actually use it.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
April is National Minority Health Month, spotlighting the urgency to improve health outcomes in communities of color.
